ClinicalTrials.gg
CompletedNCT06437561Updated Jun 3, 2024

Report of Ten Cases of Venous Aneurysm in Extremities

An observational study in Venous Aneurysm Nos, Arteriovenous Malformations and Vascular Diseases, sponsored by Golestan University of Medical sciences. Completed at 1 site in Iran, Islamic Republic of. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Golestan University of Medical sciences · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
10
Sex
All
01

Study summary

Venous aneurysms are not common in general, but because of the inherent risk of thrombosis in aneurysms, their timely diagnosis and treatment are recommended in most of the current sources. Ten cases of venous aneurysms were diagnosed and managed in our vascular surgery department from October 2018 to January 2024. Patient information was extracted from their files retrospectively.

Read the detailed description

A vascular aneurysm is defined as the focal dilatation of a vessel. Aneurysm is classically used for arterial dilatations, although dilatations can occur in any part of the vascular system including veins. Venous aneurysms are not common in general, but with the increase in the use of duplex ultrasound, the number of cases diagnosed with venous aneurysms has recently increased. Venous aneurysms are more common in the lower limbs, and in the lower limbs, the involvement of the deep venous system is much more than the superficial venous system. According to reports, 77% of venous aneurysms are present in the lower limbs, of which 57% are in the deep venous system and 1.5% in the superficial venous system.

Considering their rarity, venous aneurysms may cause diagnostic challenges in some cases.

The importance of these aneurysms, especially in the lower limbs, which inherently have relative stasis due to the opposite flow direction of gravity, is that by creating venous stasis and whirlwind blood flow inside the aneurysm, they increase the susceptibility to clotting. Also, due to dysfunction of the pigeon nest valves, they cause chronic venous insufficiency. Although clot formation and subsequent pulmonary embolism are more common in deep venous aneurysms, cases of pulmonary embolism secondary to superficial venous aneurysms of the lower limbs have also been reported.

Complications caused by chronic venous insufficiency are more common in aneurysms that occur at the main junctions of superficial and deep veins, including saphenous femoral and saphenous popliteal junctions.

Considering the possible complications mentioned about venous aneurysms, these aneurysms need treatment, regardless of their location, and although in the superficial system, surgical resection is the most commonly recommended method, other surgical methods such as aneurysmectomy and primary repair, resection, and graft interposition, and also endovascular methods have been used. Of course, in case of insufficiency in the venous system, specific treatment of the cause of insufficiency (such as stripping of the large saphenous vein) is necessary in addition to the treatment of the aneurysm.

Regarding the follow-up after the treatment of aneurysms of the superficial system, most articles have recommended short-term treatment with anticoagulants and control of the superficial and deep systems through color doppler.

In this case series, we present 10 cases of venous aneurysms and discuss their presentation, diagnosis, and management.

02

Conditions studied

  • Venous Aneurysm Nos
  • Arteriovenous Malformations
  • Vascular Diseases

Keywords

  • aneurysm
  • venous malformation
  • vascular surgery
03

In context

Arteriovenous Malformations

92 studies on the registry are indexed under Arteriovenous Malformations; 29 are open to participants now.

This study's enrollment of 10 is below the median of 100 across 41 observational studies indexed under Arteriovenous Malformations.

Browse Arteriovenous Malformations studies →

Lead sponsor

Golestan University of Medical sciences is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

all patients with extremity venous aneurysm since 2018 to 2024

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of venous aneurysm

Exclusion criteria

Exclusion Criteria:

  • Patient's non-consent
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
10 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. clinical presentation of extremity venous aneurysms

    different clinical presentations of extremity venous aneurysms and their prevalence

    Time frame: 6 years

  2. age distribution of extremity venous aneurysms

    prevalence of extremity venous aneurysms in different ages

    Time frame: 6 years

  3. location distribution of extremity venous aneurysms

    prevalence of extremity venous aneurysms in upper vs. lower limbs as well as left side vs. right side

    Time frame: 6 years

  4. sex distribution of extremity venous aneurysms

    prevalence of extremity venous aneurysms in both sexes

    Time frame: 6 years

07

Study locations

1 site
  • Pezhman Kharazm, MD
    Gorgan, Golestan 4917956808, Iran, Islamic Republic of
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Mar 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2024
First posted
May 31, 2024
StartActual
Feb 13, 2024
Primary completionActual
Mar 11, 2024
CompletionActual
Mar 15, 2024
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06437561
Lead sponsor
Golestan University of Medical sciences
Responsible party
Pezhman Kharazm, MD (Vascular Surgeon, Golestan University of Medical sciences) — Principal investigator
First posted
May 31, 2024
Start date
Feb 13, 2024
Primary completion
Mar 11, 2024
Completion
Mar 15, 2024
Last update
Jun 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion